PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 6148215-0 1984 Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. Warfarin 90-98 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 3276317-3 1988 It would appear that there is greater stereoselective control in the interaction of warfarin with cytochrome P-450 enzymes than that observed for interaction with the receptor, vitamin K1 epoxide reductase. Warfarin 84-92 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 98-114 3276317-4 1988 Indeed, warfarin has been developed as a powerful stereochemical probe for in vitro studies of the terminal enzyme in the mixed-function oxidase system, cytochrome P-450. Warfarin 8-16 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 153-169 2895455-5 1987 The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring. Warfarin 50-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 68-84 3333881-8 1987 Apart from its clinical and rodenticidal uses, warfarin is an excellent substrate for probing the heterogeneity of cytochrome P.450, since its metabolic oxidation is mediated by this mixed function oxidase. Warfarin 47-55 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 115-131 6096071-13 1984 The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450. Warfarin 45-53 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-155 6747992-0 1984 The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system. Warfarin 39-47 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 70-86 6747992-5 1984 On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed. Warfarin 104-112 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 160-176 6747992-5 1984 On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed. Warfarin 104-112 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 306-322 6747992-5 1984 On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed. Warfarin 253-261 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 160-176 6747992-5 1984 On the basis of these results, the hemiketal form is proposed as the preferred solution conformation of warfarin in the lipid environment of the active site of cytochrome P-450 and the relationship between solution conformation and stereoselectivity of warfarin metabolism by beta-naphthoflavone inducible cytochrome P-450 is discussed. Warfarin 253-261 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 306-322 6148215-2 1984 In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions. Warfarin 61-69 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 149-165 6148215-2 1984 In vitro microsomal metabolism of the R and S enantiomers of warfarin to dehydrowarfarin and 4"-, 6-, 7-, 8-, and 10-hydroxywarfarin is catalyzed by cytochrome P-450 isozymes and was used as the basis for evaluating similarities and differences between human cytochrome P-450 isozyme compositions. Warfarin 61-69 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 259-275 6148215-8 1984 Based on the known warfarin metabolite profiles of five purified cytochrome P-450 isozymes, the isozyme composition of the microsomes can be estimated. Warfarin 19-27 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 65-81 6860533-4 1983 It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin. Warfarin 190-202 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 86-102 6860533-4 1983 It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin. Warfarin 281-293 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 86-102 31893-0 1979 Cumene hydroperoxide-supported microsomal hydroxylations of warfarin--a probe of cytochrome P-450 multiplicity and specificity. Warfarin 60-68 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 81-97 32112562-3 2020 Because renal dysfunction induces changes in drug metabolism and protein binding that could alter cytochrome P450 inhibition mechanisms, we hypothesized that renal dysfunction alters the impact of the warfarin-amiodarone DDI. Warfarin 201-209 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 98-113 28118749-0 2018 Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants. Warfarin 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 34-50 29858511-3 2018 Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors. Warfarin 169-177 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 26-41 29858511-3 2018 Clinical relevance of the cytochrome P450 (CYP) polymorphism related to dose, effectiveness and/or toxicity of key drugs are presented in this review, including that of warfarin, clopidogrel, tricyclic antidepressants, and proton pump inhibitors. Warfarin 169-177 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 43-46 30689138-4 2019 Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible. Warfarin 73-81 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 31-46 30689138-4 2019 Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible. Warfarin 73-81 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 48-51 30689138-4 2019 Since the induction of certain cytochrome P450 (CYP) enzymes accelerates warfarin metabolism, using CYP inducers, such as phenobarbital, to accelerate brodifacoum clearance seems plausible. Warfarin 73-81 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 100-103 28686070-0 2018 Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Warfarin 111-119 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 78-93 28118749-1 2018 Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR). Warfarin 80-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 28118749-1 2018 Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR). Warfarin 80-88 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 32-35 28118749-1 2018 Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR). Warfarin 156-164 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-30 28118749-1 2018 Initiation of cytochrome P-450 (CYP)-inducing anticonvulsant medications during warfarin therapy may decrease anticoagulant effect and necessitate frequent warfarin dose adjustments to maintain therapeutic response measured by the international normalized ratio (INR). Warfarin 156-164 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 32-35 26161443-2 2014 Enantiomeric separation and quantification of warfarin enantiomers and clinically important major hydroxylation metabolites are essential for drug interaction studies and phenotypic characterization of CYP2C9 and CYP3A4, the major cytochrome P450 (CYP) enzymes involved in warfarin metabolism. Warfarin 46-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 231-246 26161443-2 2014 Enantiomeric separation and quantification of warfarin enantiomers and clinically important major hydroxylation metabolites are essential for drug interaction studies and phenotypic characterization of CYP2C9 and CYP3A4, the major cytochrome P450 (CYP) enzymes involved in warfarin metabolism. Warfarin 46-54 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 202-205 15767245-6 2005 We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Warfarin 55-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 148-163 22317799-4 2012 Ideally, such an assay would use a single PCR reaction and, without further processing, a single microchip electrophoresis (ME) run to determine the 3 single-nucleotide polymorphisms (SNPs) affecting warfarin sensitivity [i.e., CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) *2, CYP2C9 *3, and the VKORC1 (vitamin K epoxide reductase complex 1) A/B haplotype]. Warfarin 200-208 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 236-261 19356015-2 2007 The CYP form with the lowest in vitro K(i) is evaluated first clinically, employing a suitable probe drug like midazolam (CYP3A4), theophylline (CYP1A2), (S)-warfarin (CYP2C9) and desipramine (CYP2D6), and the NCE is classified as a "none", "weak", "moderate", or "strong" inhibitor. Warfarin 156-166 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 4-7 16162970-8 2005 Potent cytotoxic activity of ET-743 after 120 h treatment was observed, which could be increased in combination with the CYP inhibitors metyrapone (3A4), phenanthrene (substrate for 2E1, 3A4), piperonyl butoxide (3A), proadifen (2C9, 2E1, 3A4), ritonavir (3A4), and warfarin (2C9, 2C19). Warfarin 266-274 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 121-124 20002088-4 2009 * This cocktail can be used to test the effects of a new chemical entity on multiple CYP isoforms in a single clinical study: CYP1A2 (caffeine), CYP2C9 (warfarin), CYP2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A (midazolam) and was designed to overcome potential liabilities of other reported cocktails. Warfarin 153-161 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 85-88 18838506-1 2009 In vitro experiments were conducted to compare k(inact), K(I) and inactivation efficiency (k(inact)/K(I)) of cytochrome P450 (P450) 2C9 by tienilic acid and (+/-)-suprofen using (S)-flurbiprofen, diclofenac, and (S)-warfarin as reporter substrates. Warfarin 212-224 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 109-135 17708140-5 2007 Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes. Warfarin 18-26 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 96-111 16639745-1 2006 To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin. Warfarin 170-178 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 109-124 16639745-1 2006 To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin. Warfarin 170-178 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 126-129 16639745-1 2006 To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin. Warfarin 274-282 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 109-124 16639745-1 2006 To examine the molecular basis of activity and regioselectivity of the clinically important human microsomal cytochrome P450 (CYP) monooxygenase 2C9 toward its substrate warfarin, 22 molecular dynamics simulations (3-5 ns each) were performed in the presence and absence of warfarin. Warfarin 274-282 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 126-129 15767245-6 2005 We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Warfarin 55-63 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 165-168 15767245-6 2005 We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Warfarin 116-124 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 148-163 15767245-6 2005 We propose that the increased antithrombotic effect of warfarin involved protein-binding interactions and decreased warfarin metabolism through the cytochrome P450 (CYP) enzyme system. Warfarin 116-124 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 165-168 15197521-1 2004 OBJECTIVE: This study aimed to investigate the importance of cytochrome P(450) enzymes for the reported interaction between tramadol and warfarin. Warfarin 137-145 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 61-78 12814453-1 2003 AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP). Warfarin 122-130 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 162-178 12728288-1 2003 BACKGROUND: In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450-CYP2C9 have recently been associated with very low warfarin requirements. Warfarin 53-61 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 89-112 12728288-1 2003 BACKGROUND: In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450-CYP2C9 have recently been associated with very low warfarin requirements. Warfarin 157-165 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 89-112 12814453-1 2003 AIMS: Nafcillin (Wyeth Laboratories, Philadelphia, PA, USA) has been reported to induce the metabolism of cyclosporin and warfarin, which are known substrates of cytochrome P-450 (CYP). Warfarin 122-130 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 180-183 11893129-3 2002 To better understand the interaction between genotype and response to warfarin therapy, we determined the frequency and functional effects of polymorphisms of the predominant cytochrome P450 subfamily responsible for warfarin metabolism (eg, CYP2C9) in an ethnically defined U.S. patient population. Warfarin 70-78 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 175-190 11893129-3 2002 To better understand the interaction between genotype and response to warfarin therapy, we determined the frequency and functional effects of polymorphisms of the predominant cytochrome P450 subfamily responsible for warfarin metabolism (eg, CYP2C9) in an ethnically defined U.S. patient population. Warfarin 217-225 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 175-190 11893129-11 2002 Patients with CYP polymorphisms (2C9*2, 2C9*3) had significantly lower warfarin doses compared to patients with wild-type genotypes [30.6 (+/- 2.5) mg versus 40.1 (+/- 1.7) mg, p = 0.0021] . Warfarin 71-79 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 14-17 11893129-12 2002 Stepwise backward regression analysis suggested a moderate ability to predict warfarin dose based on CYP genotype (r2 = 0.26), p < 0.01). Warfarin 78-86 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-104 11893129-14 2002 As interactions between genetic factors and other variables that influence warfarin effect are more completely understood, CYP analysis may prove a useful adjunct for increasing the safety and efficacy of this agent. Warfarin 75-83 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 123-126 11343389-0 2001 Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms. Warfarin 8-16 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 66-81 11343389-2 2001 Warfarin is metabolized by two distinct subfamilies of the cytochrome P450 (CYP) complex. Warfarin 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 59-74 11343389-2 2001 Warfarin is metabolized by two distinct subfamilies of the cytochrome P450 (CYP) complex. Warfarin 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 76-79 11343389-3 2001 We describe two siblings with extreme sensitivity to warfarin who share an unusual CYP genotype. Warfarin 53-61 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 83-86 9068934-8 1997 The metabolism of warfarin is principally mediated by the cytochrome P450 (CYP) isoenzyme CYP2C9/10. Warfarin 18-26 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 58-73 11523725-3 2001 Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients. Warfarin 101-109 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 32-47 11523725-3 2001 Pharmacogenetic polymorphism of cytochrome P450 (CYP) may be associated with impaired elimination of warfarin and exaggerated anticoagulatory responses to the drug in certain patients. Warfarin 101-109 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 49-52 10923005-0 2000 Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Warfarin 58-66 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 0-15 10923005-2 2000 Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP) complex. Warfarin 41-49 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 109-124 10923005-2 2000 Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP) complex. Warfarin 41-49 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 126-129 10923005-3 2000 The purpose of this study was to ascertain the frequency and influence of CYP polymorphisms on warfarin dosing in our patient population. Warfarin 95-103 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 74-77 9068934-8 1997 The metabolism of warfarin is principally mediated by the cytochrome P450 (CYP) isoenzyme CYP2C9/10. Warfarin 18-26 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 75-78 1581537-0 1992 Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Warfarin 17-25 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 50-66 8801056-2 1996 The antifungal agent fluconazole was found to be a potent inhibitor of cytochrome P450 (P450) 2C9 (Ki = 7-8 microM), the principal enzyme responsible for the clearance (85%) of the more potent anticoagulant (S)-warfarin to the inactive (S)-7- and (S)-6-hydroxywarfarin metabolites in vivo. Warfarin 211-219 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 71-97 8801058-3 1996 The results of studies of the effect of fluconazole on cytochrome P450 (P450) 2C9 activity in vivo and in vitro are used to develop an approach to the safe management of the warfarin-fluconazole drug interaction. Warfarin 174-182 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 55-81 8801056-1 1996 I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Warfarin 67-75 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 27-42 1581537-0 1992 Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Warfarin 111-119 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 50-66 1581537-3 1992 In order to identify the specific form(s) of human liver cytochrome P-450 involved in this particular toxicity, we have determined the metabolic profiles of 11 human cytochrome P-450 forms expressed in HepG2 cells toward both (R)- and (S)-warfarin. Warfarin 239-247 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 57-73